Residual Variants May Predict Relapse, Death in AML
Residual variants are associated with a higher risk of relapse and death among AML patients undergoing HSCT in first remission, a study suggests.
Residual variants are associated with a higher risk of relapse and death among AML patients undergoing HSCT in first remission, a study suggests.
Iomab-B plus RIC enables ASCT in a population of AML patients who are not typically eligible for transplant, a phase 3 study suggests.
Phase 3 trial results support the use of carfilzomib, lenalidomide, and dexamethasone as maintenance after autologous stem cell transplant in patients with multiple myeloma.
Posoleucel appears safe and effective for treating refractory viral infections occurring after allogeneic hematopoietic stem cell transplant.
Researchers observed improvements in overall survival and progression-free survival with peripheral blood vs bone marrow transplants.
Undergoing HSCT within 4 weeks of SARS-CoV-2 infection is associated with an increased risk of death at 90 days after HSCT, real-world data suggest.
PTCy plus tacrolimus and MMF should be standard GVHD prophylaxis in adults who receive a well-matched PBSCT after RIC, according to researchers.
Researchers sought to determine whether patients with PTCL who have a complete response after A+CHP would benefit from SCT.
Unrelated cord blood transplant can result in comparable outcomes as matched sibling donor transplant in adults with B-cell acute lymphoblastic leukemia.
First-line bendamustine plus rituximab followed by ASCT and rituximab maintenance appears effective in mantle cell lymphoma.